Zachary George, MD
Interventional Cardiology · Gainesville, GANPI 1548215825
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abiomed at 54.3% of the total. Reporting peaked in 2023 at $10,843 and has fallen 87.3% since, to $1,381 in 2025.
Across 210 payments — averaging $115.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$13K
- Abbott$3K
- Penumbra, Inc.$2K
- Inari Medical, Inc.$1K
- W. L. Gore & Associates, Inc.$1K
- Medtronic$1K
- plus $2K from 23 others
Across 22 payments — averaging $2778.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$61K
What the payments were for
- Consulting fees$2,0258%
- Speaking & faculty fees$11,25047%
- Travel & lodging$4,35618%
- Food & beverage$6,44027%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 30 | $13,125 |
| Abbott | 24 | $3,029 |
| Penumbra, Inc. | 8 | $2,159 |
| Inari Medical, Inc. | 6 | $1,327 |
| W. L. Gore & Associates, Inc. | 7 | $1,282 |
| Medtronic(2 entities) | 27 | $1,160 |
| Boston Scientific | 23 | $555 |
| Novartis | 22 | $369 |
| AstraZeneca | 10 | $198 |
| Johnson & Johnson | 10 | $168 |
| Amgen | 6 | $106 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $103 |
| Chiesi USA, Inc. | 3 | $69 |
| Cardiovascular Systems Inc. | 5 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Pfizer | 3 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Acist Medical Systems, Inc. | 1 | $36 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Philips North America LLC | 2 | $29 |
| Shockwave Medical, Inc | 1 | $22 |
| Livanova USA, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$12,506
- Indigo System$1,969
- FLOWTRIEVER CATHETER, S$1,326
- Perclose ProGlide suture mediated closure system$1,232
- CARDIOFORM Septal Occluder$1,205
- Ultreon$900
- CT THROMBECTOMY SYSTEM KIT$889
- TurboHawk$647
- ONYX FRONTIER$165
- FlowTriever$162
- ClotTriever$162
- COROFLOW$154
- Optis Coronary Imaging System$131
- Penumbra System$125
- XIENCE SKYPOINT$117
How this compares
$24,154 in reported general payments places this provider in the 75th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 208 | $273,009 |
| XareltoRivaroxaban | 109 | $136,090 |
| EntrestoSacubitril/Valsartan | 21 | $30,048 |
| Repatha SureclickEvolocumab | 25 | $22,147 |
| Metoprolol Succinate | 250 | $4,459 |
| Rosuvastatin Calcium | 302 | $4,233 |
| Atorvastatin Calcium | 250 | $3,203 |
| Losartan Potassium | 197 | $2,106 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 57 | $1,916 |
| Amlodipine Besylate | 232 | $1,725 |
| Potassium Chloride | 80 | $1,650 |
| Prasugrel Hcl | 17 | $1,542 |
| ClopidogrelClopidogrel Bisulfate | 134 | $1,372 |
| Nebivolol Hcl | 23 | $1,301 |
| Flecainide Acetate | 19 | $1,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $273,009208 claims |
| Johnson & JohnsonXarelto | $168 | $136,090109 claims |
| NovartisEntresto | $369 | $30,04821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Gainesville
- Mudassar AhmedGainesville$193K
- Stephane RinfretGainesville$72K
- Ronnie RamadanGainesville$45K
- Habib SamadyGainesville$42K
- Olga TolevaGainesville$19K
- Marc Allard-RatickGainesville$19K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.